#United States #Santa Clara #Osteoid #Invivo #TX Studio

Osteoid Inc. Announces End of Life for Invivo and TX Studio Versions

On January 2, 2025, Osteoid Inc. officially announced that its software versions Invivo and TX Studio 6.5, along with earlier iterations, will reach the End of Life (EOL) on March 31, 2025. This update marks a significant transition for users and highlights the company's commitment to providing state-of-the-art software solutions.

With the EOL approaching, Osteoid is emphasizing the need for users to upgrade to the latest version, Invivo7. This transition is not merely a matter of discontinuation; it is a move towards enhanced security, improved functionalities, and compliance with modern regulatory standards. Users who adopt Invivo7 will benefit from a suite of advanced features designed to augment their practices and protect sensitive patient data.

Why Upgrade?

There are several compelling reasons for users to consider this upgrade:

1. Simplified Licensing: Invivo7 brings a more flexible licensing structure, allowing users greater control over their software management, making it easier to adapt to evolving needs.

2. Seamless Collaboration: The introduction of Invivo Workspace enables effortless sharing of cases between colleagues and patients, fostering better communication and ensuring effective treatment planning.

3. Enhanced Security: With the ever-growing threats to data privacy, Invivo7 employs the latest security measures to safeguard both patient and user data, ensuring compliance with recognized standards.

4. Improved Features: Users will discover streamlined workflows, newly integrated tools, and advanced capabilities that significantly aid in the effective delivery of medical services.

5. Full Support: By upgrading, users gain access to comprehensive technical assistance, ensuring they receive timely updates and troubleshooting help when needed.

Support for the Upgrade Process

For users seeking assistance during this transition, Osteoid encourages them to reach out through various means:

• - Email: [email protected]
• - Phone: +1(408) 333-3484
• - Website: For further information, visit here.

Osteoid's commitment extends beyond providing software; they endeavor to support clients throughout the End of Life process, emphasizing the importance of both innovation and security in healthcare practices.

A Message from the CEO

Calvin Hur, CEO of Osteoid Inc., stated, "End-of-life transitions for medical devices are a natural part of innovation, ultimately bringing great value to our customers, their patients, and the industry. Change can feel disruptive, but our team is committed to ensuring a seamless transition." Hur confidently reassured stakeholders that the newest versions of Invivo would yield improved workflows and superior patient outcomes.

About Osteoid Inc.

Osteoid Inc. has established itself as a leading provider of advanced diagnostic and treatment planning solutions. The company's dedication to empowering healthcare professionals with innovative and secure software solutions is evident in its ongoing commitment to enhancing technology in the medical field. As the health industry evolves, Osteoid remains at the forefront, providing tools that align with both practice needs and security requirements.

In conclusion, the approaching End of Life for Invivo and TX Studio versions 6.5 and earlier serves as a call to action for users to upgrade to Invivo7, ensuring they remain equipped with the best resources available in modern healthcare.